Israel's IceCure Medical said on Sunday it received U.S. regulatory approval to expand the use of its cryoablation technology to treat benign and cancerous tumours in livers and kidneys, sending its share price up 30%. IceCure's treatment uses special needles to inject liquid nitrogen to freeze and destroy tumours without the need for surgery. It has focused on breast tumours, but now the U.S. Food and Drug Administration (FDA) approved new uses, such as against tumours in the kidney, liver and in the fields of neurology and ear, nose and throat, the company said. The FDA also approved its new MultySense system that has three probes, it said. Its earlier system had one needle.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!